A Myelodysplastic Syndromes Conference in April will discuss progress in diagnostics and treatment12 Feb. 2020
Research FOR Patients
-For an informed and empowered opinion-
Have you made your clinical paper accessible yet?
7th Translational Research Conference - April 23-25 2020 – Mandelieu-La Napoule, France
Chaired by MDS experts Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres this prestigious MDS conference will be held in the Mandelieu Congress Centre in Mandelieu-La Napoule, France.
Until recently, information on the biology of MDS and the options available for its treatment were limited.
In recent years, a lot of data has accumulated on the physiological processes associated with MDS, in particular on the role of genetic changes acquired by an affected blood cell (including in very early disease phase), and other observations at the cell level which prevent cells to function normally.
The prognosis of the disease have also been refined, with the revised IPSS, and new factors like genetic mutations.
In addition, the treatment options for MDS patients are improving, although not at the same speed, and only allogeneic stem cell transplantation (bone marrow transplant) remains potentially curative.
The 7th ESH Conference on MDS is designed to provide time and multiple opportunities for critical discussion and informal scientific interaction with internationally recognised MDS experts.
What are the learning objectives of the conference?
Clinicians and patient support groups, among others, will have the opportunity to look in depth into the following topics:
- Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also through the use of new tools, mainly molecular analysis.
- Improve ability to analyse prognostic factors, including new ones (revised IPSS, molecular analysis).
- Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation.
- Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.